COMP <GO>
ORKA vs JNJ // FORWARD P/E MULTIPLE
Oruka Therapeutics Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: ORKA 3
— JNJ 10
▲ FORWARD P/E MULTIPLE LEADER: JNJ
LAST: $96.87 (+0.23%) • MKT CAP: $6.40B
forward-pe
28.0x
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
forward-pe
23.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ORKA VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ORKA | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 67.90% | -26.90 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -18.80% | 25.50% | -44.30 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.38% | 2.97% | -4.35 | JNJ | /fcf-yield <GO> |
| Operating Margin | -6.80% | 34.70% | -41.50 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -5.90% | 28.50% | -34.40 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | -4.40% | 6.00% | -10.40 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.59 | +20.41 | ORKA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 8/9 | -4.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.30% | 7.20% | +0.10 | JNJ | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 67.2 | 60.4 | +6.83 | ORKA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.13 | 1.08 | +0.05 | ORKA | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 28.0x | 23.0x | +5.00 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $6.40B | $662.49B | -$656.09B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ORKA REV | JNJ REV | ORKA GROSS % | JNJ GROSS % | ORKA FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $94.19B | — | 67.9% | -$88.4M | $19.70B |
| FY 2024 | $0 | $88.82B | — | 69.1% | -$58.0M | $19.84B |
| FY 2023 | $0 | $85.16B | — | 44.0% | -$5.0M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ORKA // BETA 1.13
JNJ // BETA 1.08